The price of Cytokinetics Inc (NASDAQ:CYTK) shares last traded on Wall Street fell -4.21% to $52.28.
CYTK stock price is now -17.43% away from the 50-day moving average and -4.30% away from the 200-day moving average. The market capitalization of the company currently stands at $5.99B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target enhanced from $61 to $92, UBS Downgraded its rating from Buy to Neutral for Cytokinetics Inc (NASDAQ: CYTK). On January 05, 2024, Morgan Stanley Downgraded its previous ‘Overweight’ rating to ‘Equal-Weight’ on the stock increasing its target price from $60 to quote $90, while ‘Goldman’ rates the stock as ‘Buy’
In other news, Wong Robert, VP, Chief Accounting Officer sold 13,011 shares of the company’s stock on Jun 03 ’24. The stock was sold for $635,978 at an average price of $48.88. Upon completion of the transaction, the VP, Chief Accounting Officer now directly owns 16,653 shares in the company, valued at $0.87 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 03 ’24, Director PARSHALL B LYNNE sold 5,000 shares of the business’s stock. A total of $243,200 was realized by selling the stock at an average price of $48.64. This leaves the insider owning 15,600 shares of the company worth $0.82 million. A total of 3.67% of the company’s stock is owned by insiders.
During the past 12 months, Cytokinetics Inc has had a low of $25.98 and a high of $110.25. The fifty day moving average price for CYTK is $62.9362 and a two-hundred day moving average price translates $54.72405 for the stock.
The latest earnings results from Cytokinetics Inc (NASDAQ: CYTK) was released for 2024-03-31. The company reported revenue of $0.83 million for the quarter, compared to $4.61 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -81.9 percent.
